© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 90733 refers to the Meningococcal polysaccharide vaccine, specifically targeting serogroups A, C, Y, and W-135, known as quadrivalent meningococcal polysaccharide vaccine (MPSV4). This vaccine is designed for subcutaneous administration, meaning it is injected into the fatty tissue just beneath the skin. Unlike immune globulins, which offer short-term, passive immunity, vaccines like MPSV4 provide active, long-term immunity. This is achieved by exposing the recipient's immune system to altered forms of the bacteria, prompting the body to produce its own antibodies. Consequently, the immune system retains a memory of how to generate these antibodies upon future exposure to the same antigens. The MPSV4 vaccine is crucial in protecting against meningococcal disease, a severe illness caused by the bacterium Neisseria meningitidis. This pathogen is transmitted through respiratory secretions and can lead to serious health complications, including septicemia and meningitis, which may result in shock, coma, death, or long-term effects such as hearing loss or brain damage. There are 13 identified serogroups of Neisseria meningitidis, with six being responsible for the majority of global disease cases. The MPSV4 vaccine specifically protects against serogroups A, C, W-135, and Y, and is recommended for individuals aged 2 years and older. Importantly, this vaccine is composed of the outer polysaccharide capsule of the bacteria and does not contain any live virus, ensuring safety during administration. It is essential to note that this code pertains solely to the supply of the vaccine; the administration of the injection is reported separately.
© Copyright 2025 Coding Ahead. All rights reserved.
The Meningococcal polysaccharide vaccine (MPSV4) is indicated for the prevention of meningococcal disease caused by serogroups A, C, Y, and W-135. This vaccine is recommended for individuals aged 2 years and older, particularly those who may be at increased risk of exposure to Neisseria meningitidis or who are traveling to areas where the disease is prevalent.
The administration of the Meningococcal polysaccharide vaccine (MPSV4) involves several key procedural steps to ensure proper delivery and effectiveness of the vaccine.
After the administration of the Meningococcal polysaccharide vaccine (MPSV4), patients are typically advised to remain in the healthcare setting for a brief observation period to monitor for any immediate adverse reactions, such as allergic responses. Common side effects may include mild pain or swelling at the injection site, fever, or fatigue, which usually resolve on their own. Patients should be informed about the importance of reporting any unusual symptoms or reactions that may occur after leaving the facility. Additionally, it is essential to document the administration of the vaccine in the patient's medical record, including the date, site of injection, and any relevant observations made during the post-procedure monitoring period.
| Short Descr | MPSV4 VACCINE SUBQ | Medium Descr | MPSV4 VACCINE GROUPS ACYW-135 SUBQ USE | Long Descr | Meningococcal polysaccharide vaccine, serogroups A, C, Y, W-135, quadrivalent (MPSV4), for subcutaneous use | Related Drugs | MENOMUNE - A/C/Y/W-135 COMBINED | Status Code | Excluded from Physician Fee Schedule by Regulation | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Items and Services Not Billable to the MAC | Type of Service (TOS) | 1 - Medical Care | Berenson-Eggers TOS (BETOS) | O1G - Immunizations/Vaccinations | MUE | 1 | CCS Clinical Classification | 228 - Prophylactic vaccinations and inoculations |
| 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | GA | Waiver of liability statement issued as required by payer policy, individual case | GY | Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit | JZ | Zero drug amount discarded/not administered to any patient |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2016-01-01 | Changed | First appearance of change in codebook. |
| 2015-07-01 | Changed | Description Changed |
| 2011-01-01 | Changed | Short description changed. |
| 2004-01-01 | Changed | Code description changed. |
| Pre-1990 | Added | Code added. |
Get instant expert-level medical coding assistance.